Aanchal Kakkar

Aanchal Kakkar

Auto-generated profile, based on publicly available information

Aanchal Kakkar

Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2013 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
NGNishant Goyal
Nishant Goyal
AKAanchal Kakkar
Aanchal Kakkar
PSPankaj Kumar Singh
Pankaj Kumar Singh
MSMehar Chand Sharma
Mehar Chand Sharma
PCPoodipedi Sarat Chandra
Poodipedi Sarat Chandra
BSBhawani Shankar Sharma
Bhawani Shankar Sharma

1 April 2018 in Auris Nasus Larynx
Verified
Journal Article
Closed access
SKShubhada V. Kane
Shubhada V. Kane
AKAanchal Kakkar
Aanchal Kakkar
NONikita Oza
Nikita Oza
ESEpari Sridhar
Epari Sridhar
PPPrathamesh S. Pai
Prathamesh S. Pai

1 November 2013 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
RGRakesh Kumar Gupta
Rakesh Kumar Gupta
MSMehar C. Sharma
Mehar C. Sharma
VSVaishali Suri
Vaishali Suri
AKAanchal Kakkar
Aanchal Kakkar
MSManmohan Singh
Manmohan Singh
CSChitra Sarkar
Chitra Sarkar

1 July 2019 in Mediastinum
Verified
Journal Article
Open access
AKAanchal Kakkar
Aanchal Kakkar
KKKavneet Kaur
Kavneet Kaur
AVAjay Verma
Ajay Verma
Mediastinal germ cell tumors (GCTs) are a rare and heterogeneous group of neoplasms. Although histologically resembling their gonadal counterparts, they differ considerably in their clinical characteristics, biological behavior and prognostic outcome. The rarity of mediastinal GCTs has hindered their meaningful analysis, with most studies and clinical trials including them along with other extragonadal GCTs, which has led to a lack of consensus on optimal treatment strategies, and a lull in improvement in patient outcomes. Diagnosis of mediastinal GCT requires a multipronged approach, and encompasses multidisciplinary treatment including chemotherapy followed by surgery, with or without radiotherapy. In view of sustained response rates to current management protocols, the focus needs to be shifted to identifying patients in whom treatment regimens can be downscaled with the aim of decreasing long term morbidity and improving quality of life in low risk patient groups, while improving survival rates in poor risk patient subsets. In this scenario, better understanding of the molecular pathogenesis of these tumors may lead to identification of novel biomarkers and therapeutic targets, as well as improved disease segmentation and risk stratification, thus helping to avoid the toxicity and morbidity associated with current one-fits-all treatment strategies. Multi-institutional collaborations across continents are necessary to generate meaningful data, and are the face of future developments in this arena.

8 January 2019 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
AKAanchal Kakkar
Aanchal Kakkar
PSPirabu Sakthivel
Pirabu Sakthivel
MRMadhu Rajeshwari
Madhu Rajeshwari
AKArvind Kairo
Arvind Kairo
MSMehar C. Sharma
Mehar C. Sharma

1 September 2022 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SMSuresh Mani
Suresh Mani
RKRajeev Kumar
Rajeev Kumar
AKAanchal Kakkar
Aanchal Kakkar
ABAdarsh Barwad
Adarsh Barwad
KDKondamudi Dheeraj
Kondamudi Dheeraj
Rakesh Kumar PilaniaRakesh Kumar Pilania
Rakesh Kumar Pilania